A new cell therapy sector arising from the convergence of cell and gene therapy
Emily J Culme-Seymour(GlaxoSmithKline (United Kingdom)), Chris Mason(Oak Ridge National Laboratory), DK Smith(Lonza (United States)), Simon Edwards‐Parton(University College London), W. Folkerts(Lonza (United States)), Jessica Carmen(Lonza (United States))
Cited by 2
Related Papers
A Brief Definition of Regenerative Medicine
|Regenerative Medicine|2007|795
BTRFS
|ACM Transactions on Storage|2013|381
Lancet Commission: Stem cells and regenerative medicine
|The Lancet|2017|276
Cell Therapy Industry: Billion Dollar Global Business with Unlimited Potential
|Regenerative Medicine|2011|144
Peak Serum: Implications of Serum Supply for Cell Therapy Manufacturing
|Regenerative Medicine|2011|144